

Press Release

4th February 2022, Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of Pharmaceutical (APIs) and Specialty Chemicals today posted its audited financial results for the quarter and nine months ending 31st December 2021. The Company on QoQ basis recorded 3% growth in total income, the EBITDA has been increased by about 26% on QoQ basis.

December 2021 vis a vis September 2021:

Rs Crore

Particulars	Quarter ended		
	31.12.2021	30.09.2021	%age
Total income	564	548	3%
EBIDTA	68	54	26%
Profit before Tax	55	42	31%
Profit after Tax	40	31	29%

Nine months ended December 2021 vis a vis Nine months ended December 2020

Rs Crore

Particulars	Nine months ended		
	31.12.2021	31.12.2020	%age
Total income from operations	1637	1525	7%
EBIDTA	238	499	-52%
Net Profit before Tax	200	465	-57%
Net Profit after Tax	138	369	-63%

Dr Sanjay Chaturvedi, Chief Executive Officer said "the continuous volatility in the Chemicals pricing and lower volume of API products has impacted our margins on YoY basis while Q3 results show significant improvement from Q2.

During Q3, the Company filed 4 DMFs with USFDA and 6 products have got GMP certificate from MOH Russia. Additionally, the company got approval from KFDA (Korean FDA) for 2 products. All these regulatory approvals will enable the Company for increased market penetration and add value to the business.

With shaping up of improved operational efficiencies, cost cutting measures and investment in human capital, we are confident that the Company is on the way to sustainable growth."

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.